Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
Portfolio Pulse from
Novartis' oral drug Fabhalta® (iptacopan) has received a positive opinion from the CHMP of the EMA for treating C3 glomerulopathy in adults, marking a significant step towards its marketing authorization.
February 28, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Fabhalta® (iptacopan) has received a positive opinion from the CHMP, which is a significant step towards obtaining marketing authorization from the EMA for treating C3 glomerulopathy.
The positive CHMP opinion is a crucial step in the regulatory process, indicating a high likelihood of EMA approval. This can lead to increased market potential and revenue for Novartis, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90